资讯

• Key Intrahepatic cholangiocarcinoma pipeline therapies in various stages of development include Zanidatamab, Derazantinib, MIV-818, Bemarituzumab, KIN-3248, TYRA-200, Nelitolimod, and others.
Cholangiocarcinoma, also known as bile duct cancer, is a rare disease. It's a devastating condition incurable at the point where it's diagnosed, which can be late given the small number of bile duct ...
The efforts of three friends to support a workmate who’s fighting cancer have drawn an amazing response from folk in Moray. Nikki Simpson, who works at the Bishopmill Pharmacy in Elgin, was diagnosed ...
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $75.7, with a high estimate of $107.00 and a low estimate of $60.00. Marking an increase of ...
A Lancet study projects a surge in liver cancer cases, reaching 1.52 million by 2050, primarily driven by obesity. Deaths are ...
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercialising ...
访问《中国科学:生命科学》官方网站(life.scichina.com)可免费下载全文COVER ARTICLESLC39A10 is a key zinc transporter in T cells and its loss mitigates autoimmune diseaseYichang Shao, Qingdian Mu, Rong Wang, Hongbin Luo, Zijun ...
The number of liver cancer cases is expected to double by 2050, with rising obesity rates partly responsible, researchers ...
Recursion Pharmaceuticals RXRX and Relay Therapeutics RLAY are pioneering the use of artificial intelligence (AI) in drug ...
In terms of consensus rating, Incyte is in the middle compared to its peers. Incyte has the highest revenue growth among its peers. Incyte also has the highest gross profit. However, Incyte has the ...
Australia's Pharmaceutical Benefits Scheme will have its second overhaul in three years with new laws to lower the maximum ...
NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended regulators approve Servier's IDH1/2 inhibitor Voranigo (vorasidenib) as a treatment for ...